Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
MetadataShow full item record
CitationZhao, Zheng, Hong Wu, Li Wang, Yi Liu, Stefan Knapp, Qingsong Liu, and Nathanael S. Gray. 2014. “Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?” ACS Chemical Biology 9 (6): 1230-1241. doi:10.1021/cb500129t. http://dx.doi.org/10.1021/cb500129t.
AbstractThe ATP site of kinases displays remarkable conformational flexibility when accommodating chemically diverse small molecule inhibitors. The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a ‘DFG-in’ and an inactive state assuming a ‘DFG-out’ conformation. Compounds that preferentially bind to the DFG-out conformation are typically called ‘type II’ inhibitors in contrast to ‘type I’ inhibitors that bind to the DFG-in conformation. This review surveys the large number of type II inhibitors that have been developed and provides an analysis of their crystallographically determined binding modes. Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:12406535